Fungal echinocandin resistance.

Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88

Early-onset neonatal sepsis. Clin Microbiol Rev (2014) 1.53

Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation. AMB Express (2015) 1.39

Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.30

Chitin synthesis and fungal pathogenesis. Curr Opin Microbiol (2010) 1.30

Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother (2011) 1.25

Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother (2013) 1.19

Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11

Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs (2014) 1.10

The MAP kinase MpkA controls cell wall integrity, oxidative stress response, gliotoxin production and iron adaptation in Aspergillus fumigatus. Mol Microbiol (2011) 1.09

Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother (2011) 1.07

Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell (2011) 1.07

The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence (2012) 1.03

In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother (2011) 1.00

Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob Agents Chemother (2011) 0.99

Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species. J Clin Microbiol (2012) 0.98

Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother (2013) 0.97

Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother (2011) 0.93

Echinocandin Resistance in Candida. Clin Infect Dis (2015) 0.93

Coping with stress and the emergence of multidrug resistance in fungi. PLoS Pathog (2015) 0.92

Chitin synthases with a myosin motor-like domain control the resistance of Aspergillus fumigatus to echinocandins. Antimicrob Agents Chemother (2012) 0.92

Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J Biol Chem (2010) 0.92

Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A. BMC Microbiol (2011) 0.91

Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol (2013) 0.90

Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination. Antimicrob Agents Chemother (2011) 0.89

Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities. PLoS One (2012) 0.89

Nonsex genes in the mating type locus of Candida albicans play roles in a/α biofilm formation, including impermeability and fluconazole resistance. PLoS Pathog (2012) 0.87

Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci (2015) 0.84

Receptor-mediated signaling in Aspergillus fumigatus. Front Microbiol (2013) 0.83

Expression of Paracoccidioides brasiliensis AMY1 in a Histoplasma capsulatum amy1 mutant, relates an α-(1,4)-amylase to cell wall α-(1,3)-glucan synthesis. PLoS One (2012) 0.83

pH signaling in human fungal pathogens: a new target for antifungal strategies. Eukaryot Cell (2014) 0.82

Caspofungin affects growth of Paracoccidioides brasiliensis in both morphological phases. Antimicrob Agents Chemother (2010) 0.82

Adaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells. Cell Rep (2016) 0.82

Candida parapsilosis and Candida guillermondii: emerging pathogens in nail candidiasis. Indian J Dermatol (2014) 0.81

Resistance to antifungals that target CYP51. J Chem Biol (2014) 0.81

Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy. Antimicrob Agents Chemother (2015) 0.80

Combinatorial strategies for combating invasive fungal infections. Virulence (2016) 0.80

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int J Nanomedicine (2013) 0.80

Breakthrough filamentous fungal infections in pediatric hematopoetic stem cell transplant and oncology patients receiving caspofungin. Can J Infect Dis Med Microbiol (2012) 0.79

The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front Microbiol (2015) 0.79

Using Aspergillus nidulans to identify antifungal drug resistance mutations. Eukaryot Cell (2013) 0.77

The PathoYeastract database: an information system for the analysis of gene and genomic transcription regulation in pathogenic yeasts. Nucleic Acids Res (2016) 0.76

Chromosome 5 of Human Pathogen Candida albicans Carries Multiple Genes for Negative Control of Caspofungin and Anidulafungin Susceptibility. Antimicrob Agents Chemother (2016) 0.76

Treatment and prophylaxis of invasive candidiasis. Semin Perinatol (2012) 0.76

New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B. Antimicrob Agents Chemother (2015) 0.76

In Vitro Antifungal Activity of Sertraline and Synergistic Effects in Combination with Antifungal Drugs against Planktonic Forms and Biofilms of Clinical Trichosporon asahii Isolates. PLoS One (2016) 0.75

Genome Anatomy of Pyrenochaeta unguis-hominis UM 256, a Multidrug Resistant Strain Isolated from Skin Scraping. PLoS One (2016) 0.75

Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol (2014) 0.75

Fungal echinocandin resistance. F1000 Biol Rep (2010) 0.75

The paradoxical effect of echinocandins in Aspergillus fumigatus relies on recovery of the β-1,3-glucan synthase Fks1. Antimicrob Agents Chemother (2016) 0.75

Evaluation of Virulence Factors In vitro, Resistance to Osmotic Stress and Antifungal Susceptibility of Candida tropicalis Isolated from the Coastal Environment of Northeast Brazil. Front Microbiol (2016) 0.75

Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling. Antimicrob Agents Chemother (2017) 0.75

Analysis of sphingolipids, sterols and phospholipids in human pathogenic Cryptococcus strains. J Lipid Res (2017) 0.75

Dirhamnolipids secreted from Pseudomonas aeruginosa modify anjpegungal susceptibility of Aspergillus fumigatus by inhibiting β1,3 glucan synthase activity. ISME J (2017) 0.75

In vitro Antibiofilm Activity of Eucarobustol E against Candida albicans. Antimicrob Agents Chemother (2017) 0.75

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45

Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol (2006) 6.36

Echinocandin antifungal drugs. Lancet (2003) 5.92

Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2005) 5.46

An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol (2008) 5.13

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 4.89

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70

Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 4.56

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol (2007) 3.57

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2001) 3.28

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother (2006) 3.27

Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol (1995) 3.27

Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun (2004) 3.21

Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19

Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother (2009) 3.13

Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother (2008) 3.05

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother (2004) 2.96

Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95

The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol (2007) 2.88

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother (2006) 2.76

Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol (2006) 2.76

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis (2006) 2.75

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother (2005) 2.75

Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother (2007) 2.74

Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother (2006) 2.68

Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun (2003) 2.67

A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog (2006) 2.65

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother (2002) 2.60

Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol (2007) 2.60

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol (2006) 2.53

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother (2008) 2.44

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38

Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother (2006) 2.37

Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother (2005) 2.35

Histoplasma capsulatum alpha-(1,3)-glucan blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A (2007) 2.34

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy (2006) 2.30

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother (2004) 2.28

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother (2006) 2.22

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20

Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog (2008) 2.19

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother (2006) 2.19

Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother (2007) 2.18

Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog (2008) 2.14

Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother (2008) 2.13

Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06

Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis (2007) 2.04

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol (2006) 2.00

The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell (2003) 2.00

The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol (2007) 2.00

Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00

The global transcriptional response to transient cell wall damage in Saccharomyces cerevisiae and its regulation by the cell integrity signaling pathway. J Biol Chem (2004) 1.99

Genome-wide analysis of the response to cell wall mutations in the yeast Saccharomyces cerevisiae. J Biol Chem (2003) 1.99

Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem (2003) 1.94

Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol (2009) 1.93

Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88

Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis (2008) 1.82

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76

Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76

Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75

Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog (2007) 1.74

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72

Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol (2008) 1.67

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66

Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol (2005) 1.61

Coping with stress: calmodulin and calcineurin in model and pathogenic fungi. Biochem Biophys Res Commun (2003) 1.61

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol (2003) 1.59

Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab (2001) 1.58

Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. PLoS Pathog (2006) 1.57

Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 1.55

Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.54

Glucan synthase complex of Aspergillus fumigatus. J Bacteriol (2001) 1.52

Investigating the caffeine effects in the yeast Saccharomyces cerevisiae brings new insights into the connection between TOR, PKC and Ras/cAMP signalling pathways. Mol Microbiol (2006) 1.48

The high osmotic response and cell wall integrity pathways cooperate to regulate transcriptional responses to zymolyase-induced cell wall stress in Saccharomyces cerevisiae. J Biol Chem (2009) 1.46

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother (2001) 1.45

The sequential activation of the yeast HOG and SLT2 pathways is required for cell survival to cell wall stress. Mol Biol Cell (2008) 1.45

A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.44

Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother (2008) 1.38

Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol (2005) 1.37

Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36

Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother (2007) 1.36

Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2004) 1.34

Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 1.33

Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother (2007) 1.33

Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol (2008) 1.33

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother (2007) 1.31

Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis (2008) 1.29

Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother (2007) 1.26

Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother (2006) 1.25

Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother (2006) 1.24

Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother (2007) 1.23

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23

Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother (2000) 1.23

Characterization of the transcriptional response to cell wall stress in Saccharomyces cerevisiae. Yeast (2004) 1.22

Hidden killers: human fungal infections. Sci Transl Med (2012) 7.10

Genome sequence and analysis of the Irish potato famine pathogen Phytophthora infestans. Nature (2009) 6.44

Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature (2009) 5.90

An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol (2008) 5.13

Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest (2006) 4.45

Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol (2005) 3.93

Antifungal agents: mechanisms of action. Trends Microbiol (2003) 3.74

A human-curated annotation of the Candida albicans genome. PLoS Genet (2005) 3.04

Ectopic expression of URA3 can influence the virulence phenotypes and proteome of Candida albicans but can be overcome by targeted reintegration of URA3 at the RPS10 locus. Eukaryot Cell (2004) 2.63

Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol (2008) 2.62

EST mining and functional expression assays identify extracellular effector proteins from the plant pathogen Phytophthora. Genome Res (2003) 2.57

Molecular phylogenetics of Candida albicans. Eukaryot Cell (2007) 2.41

Comparative genomics of the fungal pathogens Candida dubliniensis and Candida albicans. Genome Res (2009) 2.24

Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis (2007) 2.24

Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog (2008) 2.19

Optimization and validation of multilocus sequence typing for Candida albicans. J Clin Microbiol (2003) 2.18

Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cell Microbiol (2006) 2.12

Population structure and properties of Candida albicans, as determined by multilocus sequence typing. J Clin Microbiol (2005) 2.04

The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol (2007) 2.00

Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. J Biol Chem (2005) 1.95

Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol (2009) 1.93

One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol (2007) 1.87

The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol (2011) 1.76

Candida albicans Pmr1p, a secretory pathway P-type Ca2+/Mn2+-ATPase, is required for glycosylation and virulence. J Biol Chem (2005) 1.70

Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol (2008) 1.67

Comparative genomics of MAP kinase and calcium-calcineurin signalling components in plant and human pathogenic fungi. Fungal Genet Biol (2009) 1.66

Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence. J Biol Chem (2004) 1.66

Multilocus sequence typing for differentiation of strains of Candida tropicalis. J Clin Microbiol (2005) 1.66

Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect Immun (2011) 1.54

Stage specific assessment of Candida albicans phagocytosis by macrophages identifies cell wall composition and morphogenesis as key determinants. PLoS Pathog (2012) 1.54

Glucose promotes stress resistance in the fungal pathogen Candida albicans. Mol Biol Cell (2009) 1.52

Loss of cell wall mannosylphosphate in Candida albicans does not influence macrophage recognition. J Biol Chem (2004) 1.51

Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem (2008) 1.50

Infection-related gene expression in Candida albicans. Curr Opin Microbiol (2007) 1.50

Proteomic and phenotypic profiling of the amphibian pathogen Batrachochytrium dendrobatidis shows that genotype is linked to virulence. Mol Ecol (2009) 1.49

GFP as a quantitative reporter of gene regulation in Candida albicans. Yeast (2004) 1.47

Developmental regulation of an adhesin gene during cellular morphogenesis in the fungal pathogen Candida albicans. Eukaryot Cell (2007) 1.45

Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen. Cell Microbiol (2012) 1.45

Hyphal orientation of Candida albicans is regulated by a calcium-dependent mechanism. Curr Biol (2007) 1.43

Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Mol Microbiol (2003) 1.39

Genome-wide analysis of Candida albicans gene expression patterns during infection of the mammalian kidney. Fungal Genet Biol (2008) 1.37

Bypassing pathogen-induced inflammasome activation for the regulation of interleukin-1beta production by the fungal pathogen Candida albicans. J Infect Dis (2009) 1.37

Property differences among the four major Candida albicans strain clades. Eukaryot Cell (2009) 1.36

Genetic evidence for recombination in Candida albicans based on haplotype analysis. Fungal Genet Biol (2004) 1.33

Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol (2008) 1.33

Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One (2009) 1.31

Strain typing and determination of population structure of Candida krusei by multilocus sequence typing. J Clin Microbiol (2006) 1.31

Chitin synthesis and fungal pathogenesis. Curr Opin Microbiol (2010) 1.30

Endoplasmic reticulum alpha-glycosidases of Candida albicans are required for N glycosylation, cell wall integrity, and normal host-fungus interaction. Eukaryot Cell (2007) 1.29

Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1. PLoS Pathog (2013) 1.27

Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother (2011) 1.25

Toll-like receptor 9-dependent activation of myeloid dendritic cells by Deoxynucleic acids from Candida albicans. Infect Immun (2009) 1.22

Non-lytic expulsion/exocytosis of Candida albicans from macrophages. Fungal Genet Biol (2012) 1.18

Asynchronous cell cycle and asymmetric vacuolar inheritance in true hyphae of Candida albicans. Eukaryot Cell (2003) 1.18

Homologous recombination in Candida albicans: role of CaRad52p in DNA repair, integration of linear DNA fragments and telomere length. Mol Microbiol (2004) 1.17

CO(2) acts as a signalling molecule in populations of the fungal pathogen Candida albicans. PLoS Pathog (2010) 1.15

Genomic insights into the atopic eczema-associated skin commensal yeast Malassezia sympodialis. MBio (2013) 1.15

Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother (2005) 1.13

Glycosylation status of the C. albicans cell wall affects the efficiency of neutrophil phagocytosis and killing but not cytokine signaling. Med Mycol (2011) 1.12

Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin Vaccine Immunol (2014) 1.11

Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11

Cell wall glycans and soluble factors determine the interactions between the hyphae of Candida albicans and Pseudomonas aeruginosa. FEMS Microbiol Lett (2008) 1.11

Variable recognition of Candida albicans strains by TLR4 and lectin recognition receptors. Med Mycol (2010) 1.10

An internal polarity landmark is important for externally induced hyphal behaviors in Candida albicans. Eukaryot Cell (2008) 1.10

Global role of the protein kinase Gcn2 in the human pathogen Candida albicans. Eukaryot Cell (2005) 1.09

CHS8-a fourth chitin synthase gene of Candida albicans contributes to in vitro chitin synthase activity, but is dispensable for growth. Fungal Genet Biol (2003) 1.09

The evolutionary rewiring of ubiquitination targets has reprogrammed the regulation of carbon assimilation in the pathogenic yeast Candida albicans. MBio (2012) 1.08

Mechanisms of hypha orientation of fungi. Curr Opin Microbiol (2009) 1.08

Candida albicans Iff11, a secreted protein required for cell wall structure and virulence. Infect Immun (2007) 1.07

Individual chitin synthase enzymes synthesize microfibrils of differing structure at specific locations in the Candida albicans cell wall. Mol Microbiol (2007) 1.07

A multifunctional mannosyltransferase family in Candida albicans determines cell wall mannan structure and host-fungus interactions. J Biol Chem (2010) 1.04

Internuclear gene silencing in Phytophthora infestans is established through chromatin remodelling. Microbiology (2008) 1.04

Combinatorial stresses kill pathogenic Candida species. Med Mycol (2012) 1.03

Carbon source-induced reprogramming of the cell wall proteome and secretome modulates the adherence and drug resistance of the fungal pathogen Candida albicans. Proteomics (2012) 1.02

Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. PLoS Pathog (2010) 1.00

Role of Dectin-2 for host defense against systemic infection with Candida glabrata. Infect Immun (2013) 0.99

The Mnn2 mannosyltransferase family modulates mannoprotein fibril length, immune recognition and virulence of Candida albicans. PLoS Pathog (2013) 0.99

Independent regulation of chitin synthase and chitinase activity in Candida albicans and Saccharomyces cerevisiae. Microbiology (2004) 0.99

Generating cell surface diversity in Candida albicans and other fungal pathogens. FEMS Microbiol Lett (2008) 0.97

Mannosylation in Candida albicans: role in cell wall function and immune recognition. Mol Microbiol (2013) 0.97

Loss of mannosylphosphate from Candida albicans cell wall proteins results in enhanced resistance to the inhibitory effect of a cationic antimicrobial peptide via reduced peptide binding to the cell surface. Microbiology (2009) 0.97

Vacuoles and fungal biology. Curr Opin Microbiol (2008) 0.96

Calcium homeostasis is required for contact-dependent helical and sinusoidal tip growth in Candida albicans hyphae. Mol Microbiol (2009) 0.95